Comparative study of the value of dual tracer PET/CT in evaluating breast cancer

Cancer Science

Volumn 103, Issue 9, 2012, Pages 1701-1707

  Tateishi, Ukihide ^a   Terauchi, Takashi ^b   Akashi Tanaka, Sadako ^c   Kinoshita, Takayuki ^d   Kano, Daisuke ^b   Daisaki, Hiromitsu ^b   Murano, Takeshi ^b   Tsuda, Hitoshi ^d   Macapinlac, Homer A ^e  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE C 11; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FIBROCYSTIC BREAST DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MITOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CHOLINE; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; YOUNG ADULT;

EID: 84865726052     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02348.x     Document Type: Article

References (29)

1. Nieweg OE, Kim EE, Wong WH et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-5.
2. Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007; 27: S215-29.
3. Mahner S, Schirrmacher S, Brenner W et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-d-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 2008; 19: 1249-54.
4. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006; 33: 254-62.
5. Lim HS, Yoon W, Chung TW et al. FDG PET/CT for the detection and evaluation of breast diseases: usefulness and limitations. Radiographics 2007; 27: S197-213.
6. Pisano ED, Johnston RE, Chapman D et al. Human breast cancer specimens: diffraction-enhanced imaging with histologic correlation. Improved conspicuity of lesion detail compared with digital radiography. Radiology 2000; 214: 895-901.
7. Venta LA, Wiley EL, Gabriel H, Adler YT. Imaging features of focal breast fibrosis: mammographic-pathologic correlation of noncalcified breast lesions. AJR Am J Roentgenol 1999; 173: 309-16.
8. Chen JH, Liu H, Baek HM, Nalcioglu O, Su MY. Magnetic resonance imaging features of fibrocystic change of the breast. Magn Reson Imaging 2008; 26: 1207-14.
9. van den Bosch MA, Daniel BL, Mariano MN et al. Magnetic resonance imaging characteristics of fibrocystic change of the breast. Invest Radiol 2005; 40: 436-41.
10. Yutani K, Shiba E, Kusuoka H et al. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr 2000; 24: 274-80.
11. Ishidate K. Choline/ethanolamine kinase from mammalian tissues. Biochim Biophys Acta 1997; 1348: 70-8.
12. Uchida T, Yamashita S. Molecular cloning, characterization, and expression in Escherichia coli of a cDNA encoding mammalian choline kinase. J Biol Chem 1992; 267: 10156-62.
13. 11C]choline-positron emission tomography and effect of trastuzumab. Clin Cancer Res 2010; 16: 4236-45.
14. Fukukita H, Senda M, Terauchi T et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 1.0. Ann Nucl Med 2010; 24: 325-34.
15. 11C]choline, a positron-emitting tracer for tumor imaging. Appl Radiat Isot 1999; 50: 531-3.
16. Sobin LH, Wittekind C. UICC TNM Classification of Malignant Tumours, 6th edn. New York: Wiley, 2002.
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 2002; 41: 154-61.
18. McCarty KS Jr, Szabo E, Flowers JL et al. Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 1986; 46: s4244-8.
19. 11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res 2009; 15: 5503-10.
20. Neubauer H, Li M, Kuehne-Held R, Schneider A, Kaiser WA. High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. Br J Radiol 2003; 76: 3-12.
21. Guinebretière JM, Lê Monique G, Gavoille A, Bahi J, Contesso G. Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Natl Cancer Inst 1994; 86: 635-6.
22. Bodian CA, Perzin KH, Lattes R, Hoffmann P. Reproducibility and validity of pathologic classifications of benign breast disease and implications for clinical applications. Cancer 1993; 71: 3908-13.
23. Revelon G, Sherman ME, Gatewood OM, Brem RF. Focal fibrosis of the breast: imaging characteristics and histopathologic correlation. Radiology 2000; 216: 255-9.
24. Orel SG, Schnall MD, LiVolsi VA, Troupin RH. Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. Radiology 1994; 190: 485-93.
25. Fobben ES, Rubin CZ, Kalisher L, Dembner AG, Seltzer MH, Santoro EJ. Breast MR imaging with commercially available techniques: radiologic-pathologic correlation. Radiology 1995; 196: 143-52.
26. Yutani K, Tatsumi M, Uehara T, Nishimura T. Effect of patients being prone during FDG PET for the diagnosis of breast cancer. AJR Am J Roentgenol 1999; 173: 1337-9.
27. Palmedo H, Bender H, Grünwald F et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nucl Med 1997; 24: 1138-45.
28. Kole AC, Nieweg OE, Pruim J et al. Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and l-[1-11C]tyrosine. J Nucl Med 1997; 38: 692-6.
29. Yoshimoto M, Waki A, Obata A, Furukawa T, Yonekura Y, Fujibayashi Y. Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nucl Med Biol 2004; 31: 859-65.